Hemostasis disorders in patients with NSTEMI and diagnostic markers.

Authors

  • DANILA Tatiana IMSP Institutul de Cardiologie
  • MUNTEANU Mihaela IMSP Institutul de Cardiologie
  • CIOBANU Lucia IMSP Institutul de Cardiologie
  • POPOVICI Mihail IMSP Institutul de Cardiologie
  • COBEȚ VALERIU Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”

DOI:

https://doi.org/10.52692/1857-0011.2022.1-72.15

Keywords:

NSTEMI, haemostasis disorder, procoagulant markers, anticoagulant system markers, fibrinolysis markers

Abstract

Actualitate. Tulburarea hemostazei este un mecanism important al afecțiunilor cardiovasculare, iar aportul patogenetic al acestuia în evoluția NSTEMI este îndeosebi notabil în contextul semnificației paternului fiziopatologic determinat de dereglarea microcirculației coronariene. Evidențierea markerilor iminenți va facilita diagnosticul și prognosticul NSTEMI. Scopul. Relatarea datelor de sinteză a literaturii privind markerii circulanți ai tulburării hemostazei la pacienții cu NSTEMI. Rezultate. Markerii principali ai dereglării hemostazei în NSTEMI și cu valoare predictivă asupra diagnosticului și evoluției post-infarct sunt:vizavi de sistemul procoagulant: elevarea microparticulelor derivate de endoteliocite și plachete ce expresează fosfotidilserină, activarea complexului factorilor de coagulare II, VII și X, formarea agregatelor dintre plachete și leucocite;vizavi de sistemul anticoagulant: creșterea trombomodulinei solubile în asociere cu micșorarea plasmatică a antitrombinei și a proteinelor C și S;vizavi de sistemul fibrinolitic: elevarea nivelului plasmatic al monomerilor și D-dimerilor ai fibrinei, al inhibitorului activatorului plasminogenului în asociere cu deprecierea cantitativă a activatorului plasminogenului.

Author Biographies

DANILA Tatiana, IMSP Institutul de Cardiologie

cercetător științific

MUNTEANU Mihaela, IMSP Institutul de Cardiologie

doctorand

CIOBANU Lucia, IMSP Institutul de Cardiologie

dr.hab.șt.med., conf.cercetător

POPOVICI Mihail, IMSP Institutul de Cardiologie

dr.hab.șt.med., prof.univ., acad. al AȘM, șef Laboratorul științific de cardiologie intervențională

COBEȚ VALERIU, Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”

dr.hab.șt.med., prof.univ.

References

Krychtiuk KA., Speidl WS., Giannitsis E., Gigante B., Gorog DA., Jaffe AS. et al. Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. Eur Hear Journal Acute Cardiovasc Care. 2021;10(3).

Ramberg C., Jamaly S., Latysheva N., Wilsgård L., Sovershaev T., Snir O. et al. A modified clot-based assay to measure negatively charged procoagulant phospholipids. Sci Rep. 2021;11(1).

Zarà M., Guidetti GF., Camera M., Canobbio I., Amadio P., Torti M. et al. Biology and role of extracellular vesicles (Evs) in the pathogenesis of thrombosis. Vol. 20, International Journal of Molecular Sciences. 2019.

Fotiou D., Sergentanis TN., Papageorgiou L., Stamatelopoulos K., Gavriatopoulou M., Kastritis E. et al. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J. 2018;8(11).

Konkoth A., Saraswat R., Dubrou C., Sabatier F., Leroyer AS., Lacroix R. et al. Multifaceted role of extracellular vesicles in atherosclerosis. Vol. 319, Atherosclerosis. 2021.

Deng WY., Tang TT., Hou YF., Zeng Q., Wang YF., Fan WJ. et al. Extracellular vesicles in atherosclerosis. Vol. 495, Clinica Chimica Acta. 2019.

Wang L., Cao M., Bi Y., Ma R. Microparticles and blood cells induce procoagulant activity via phosphatidylserine exposure in NSTEMI patients following stent implantation. Int J Cardiology, 2016, 223. DOI:10.1016/j. ijcard.2016.07.260.

Hartopo AB., Puspitawati I., Gharini PP. et al. Platelet microparticle number is associated with the extent of myocardial damage in acute myocardial infarction. Arch Med Sci, 2016, 12(3): 529-537. DOI: 10.5114/ aoms.2016.59926.

Biassucci LM., DiVito L., DeMAria G. et al. Differences in Microparticle Release in Patients With Acute Coronary Syndrome and Stable Angina. Circulation Journal, 2012, 76: 2174-2182.

Pluta K., Porebska K., Urbanowicz T. et al. Platelet–Leucocyte Aggregates as Novel Biomarkers in Cardiovascular Diseases. Biology, 2022, 11, 224: DOI: 11, 224. https://doi.org/10.3390/biology11020224

Kosaki R., Minoura Y., Ogura K. et al. Thrmbomodulin can predict the incidence of second events in patients with acute coroanry syndrome: single-center retrospective study. Journal of Cardiology, 2018, 72(6): 494-500.

Chan S. Increasing post-event plasma thrombomodulin level associates with worse outcome in survival of acute coronary syndrome. Int J Cardiol, 2006, 111(2): 280285. DOI: 10.1016/j.ijcard.2005.09.015.

Ismail D., Harun S., Alwi I., Tambunan KL. Anti-thrombin III, Protein C, and Protein S deficiency in acute coronary syndrome. Med J of Indonesia, 2002, 11(2):87. Doi:10.13181/mji.v11i2.54.

Tiong IY., Alkotob ML., Ghaffari S. Protein C deficiency manifesting as an acute myocardial infarction and ischaemic stroke. Heart. 2003; 89(2): E7. doi:10.1136/ heart.89.2.e7

Winter WE., Greene DN., Beal SG., Isom JA., Manning H., Wilkerson G., et al. Clotting factors: Clinical biochemistry and their roles as plasma enzymes. In: Advances in Clinical Chemistry. 2020.

Babes EE., Zaha DC., Tit DM., Nechifor AC., Bungau S., Andronie-Cioara FL. et al. Value of hematological and coagulation parameters as prognostic factors in acute coronary syndromes. Diagnostics. 2021;11(5).

Pieters M., Wolberg AS. Fibrinogen and fibrin: An illustrated review. Vol. 3, Research and Practice in Thrombosis and Haemostasis. 2019.

Memtsas VP., Arachchillage DRJ., Gorog DA. Role, laboratory assessment and clinical relevance of fibrin, factor XIII and endogenous fibrinolysis in arterial and venous thrombosis. Vol. 22, International Journal of Molecular Sciences. 2021.

Refaai MA., Riley P., Mardovina T., Bell PD. The Clinical Significance of Fibrin Monomers. Vol. 118, Thrombosis and Haemostasis. 2018.

Arthamin MZ., Parmadi L., Djatmiko DP., Lawanto ER. Analysis of soluble fibrin monomer as diagnostic marker for acute myocardial infarction and its correlation with cardiac troponin. I. Indones J Clin Pathol Med Lab. 2019;25(3).

Kim JY., Kim HK., Cho Jy et al. D-dimer/troponin ratio in the differential diagnosis of acute pulmonary embolism from non-ST elevation myocardial infarction. Korean J Inter Med, 2018, 34(6): 1263-1271. DOI: 10.3904/ kjim.2018.153

Gosai F., Mital P., Vadher A. et al. D-dimerr as a marker of severity of mycoardial infarction. J of Ind Coll of Cardiol, 2015, 5(4): 269-271. DOI: https://doi.org/10.1016/j.jicc.2015.07.006.

Biccirè F.G., Farcomeni A., Gaudio C. et al. D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: a systematic review and metanalysis. Thrombosis J. 2021, 19(102). DOI: https://doi.org/10.1186/s12959-021-00354-y.

Shantsila E., Montoro-Garcia S., Tapp LD. et al. Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways. Thromb Haemost, 2012, 108(1): 3240. DOI: 10.1160/TH12-01-0011.

Chandrasekar B. Endogenous fibrinolysis inhibitors in acute coronary syndrome. Am Heart J Plus, 2021, 10, 100058. DOI: https://doi.org/10.1016/j.ahjo.2021.100058.

Published

2022-04-08